Literature DB >> 7884893

Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.

A Billich1, F Hammerschmid, P Peichl, R Wenger, G Zenke, V Quesniaux, B Rosenwirth.   

Abstract

Cyclosporins, in particular the nonimmunosuppressive derivative SDZ NIM 811, exhibit potent anti-human immunodeficiency virus type 1 (HIV-1) activity in vitro. SDZ NIM 811 interferes at two stages of the viral replication cycle: (i) translocation of the preintegration complex to the nucleus and (ii) production of infectious virus particles. Immunosuppressive activity is not correlated with anti-HIV-1 activity of cyclosporins. However, binding to cyclophilin A, the major cellular receptor protein of cyclosporins, is a prerequisite for HIV inhibition: all structural changes of the cyclosporin A molecule leading to loss of affinity to cyclophilin abolished the antiviral effect. Cyclosporin derivatives did not interact directly with HIV-1 proteins; cyclophilin was the only detectable receptor protein for antivirally active cyclosporins. There is no evidence that inhibition of HIV occurs via a gain of function of cyclophilin in the presence of cyclosporins: the complex of cyclophilin A with SDZ NIM 811 does not bind to calcineurin or to any other viral or cellular proteins under conditions in which calcineurin binding to the cyclophilin A-cyclosporin A complex is easily detectable. Thus, the loss of function caused by binding of cyclosporins to cyclophilin seems to be sufficient for the anti-HIV effect. Cyclophilin A was demonstrated to bind to HIV-1 p24gag, and the formation of complexes was blocked by cyclosporins with 50% inhibitory concentrations of about 0.7 microM. HIV-2 and simian immunodeficiency virus are only weakly or not at all inhibited by cyclosporins. For gag-encoded proteins derived from HIV-1, HIV-2, or simian immunodeficiency virus particles, cyclophilin-binding capacity correlated with sensitivity of the viruses to inhibition by cyclosporins. Cyclophilin A also binds to HIV-1 proteins other than gag-encoded proteins, namely, p17gag, Nef, Vif, and gp120env; the biological significance of these interactions is questionable. We conclude that HIV-1 Gag-cyclophilin A interaction may be essential in HIV-1 replication, and interference with this interaction may be the molecular basis for the antiviral activity of cyclosporins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7884893      PMCID: PMC188920     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS.

Authors:  D Zagury; J Bernard; R Leonard; R Cheynier; M Feldman; P S Sarin; R C Gallo
Journal:  Science       Date:  1986-02-21       Impact factor: 47.728

2.  AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications.

Authors:  J M Andrieu; P Even; A Venet
Journal:  AIDS Res       Date:  1986

3.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

4.  Molecular cloning and polymorphism of the human immune deficiency virus type 2.

Authors:  F Clavel; M Guyader; D Guétard; M Sallé; L Montagnier; M Alizon
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

5.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

6.  Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.

Authors:  M D Daniel; N L Letvin; N W King; M Kannagi; P K Sehgal; R D Hunt; P J Kanki; M Essex; R C Desrosiers
Journal:  Science       Date:  1985-06-07       Impact factor: 47.728

7.  An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells.

Authors:  R B Stricker; T M McHugh; D J Moody; W J Morrow; D P Stites; M A Shuman; J A Levy
Journal:  Nature       Date:  1987 Jun 25-Jul 1       Impact factor: 49.962

8.  Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein.

Authors:  M A Rey; B Krust; A G Laurent; D Guétard; L Montagnier; A G Hovanessian
Journal:  Virology       Date:  1989-11       Impact factor: 3.616

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  [Determination of enzymatic catalysis for the cis-trans-isomerization of peptide binding in proline-containing peptides].

Authors:  G Fischer; H Bang; C Mech
Journal:  Biomed Biochim Acta       Date:  1984
View more
  64 in total

1.  Cloning and biochemical characterization of the cyclophilin homologues from the free-living nematode Caenorhabditis elegans.

Authors:  A P Page; K MacNiven; M O Hengartner
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

2.  Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.

Authors:  Jimmy P Xu; Ashwanth C Francis; Megan E Meuser; Marie Mankowski; Roger G Ptak; Adel A Rashad; Gregory B Melikyan; Simon Cocklin
Journal:  J Drug Des Res       Date:  2018-08-13

3.  NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon.

Authors:  Sue Ma; Joanna E Boerner; ChoiLai TiongYip; Beat Weidmann; Neil S Ryder; Michael P Cooreman; Kai Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 4.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.

Authors:  Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

6.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

8.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

9.  Spontaneous mutations in the human immunodeficiency virus type 1 gag gene that affect viral replication in the presence of cyclosporins.

Authors:  C Aberham; S Weber; W Phares
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Mechanistic independence of Nef and cyclophilin A enhancement of human immunodeficiency virus type 1 infectivity.

Authors:  C Aiken
Journal:  Virology       Date:  1998-08-15       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.